Breast Cancer

In this broad study of a diverse population, adverse events associated with the combination of ribociclib plus letrozole were manageable and consistent with previous phase 3 trials of the same combination, and adverse events of special interest markedly decreased over time.
While showing comparable efficacy, the 3 approved CDK4/6 inhibitors differ in safety and tolerability profiles.
Adopting a maintenance program of everolimus combined with aromatase inhibitors, outcomes were not improved in patients with metastatic breast cancer who were deemed possible candidates for first-line chemotherapy.
Recognition of the common use of chemotherapy and its potential negative impact on quality of life during the final month of life of patients with metastatic breast cancer is essential to efforts to mitigate this practice.
Results of a second interim analysis demonstrate real-world outcomes of treatment with ribociclib, a selective CDK4/6 inhibitor in combination with endocrine therapy.
The majority of patients with metastatic breast cancer receiving treatment with CDK4/6 inhibitors had progression-free survival, behaving similarly when used as first-line therapy or after adjuvant hormonal therapy.
For patients with hormone receptor–positive, HER2-negative metastatic breast cancer, response rates for platinum-based chemotherapy were lower than historically observed in patients with triple-negative breast cancer, associated with poor outcomes.
Early locoregional therapy with surgery and radiation does not improve overall survival (OS) in women with newly diagnosed stage IV breast cancer and an intact primary tumor compared with systemic therapy alone, according to the results of the randomized ECOG-ACRIN E2108 phase 3 clinical trial.
Pembrolizumab (Keytruda) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with chemotherapy alone as a first-line treatment for patients with metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1.
San Antonio, TX—Although capecitabine (Xeloda) is approved for metasta­tic breast cancer, it is not clear whether it should be used in early breast cancer, and its optimal role remains to be established.
Page 4 of 12
Results 31 - 40 of 118